Corbus Pharmaceuticals Holdings Inc (CRBP) is now in the Fair zone, suggesting that its current forward PS ratio of 131.24 is considered Fairly compared with the five-year average of -2.69. The fair price of Corbus Pharmaceuticals Holdings Inc (CRBP) is between 4.04 to 8.57 according to relative valuation method.

Relative Value

Fair Zone

4.04-8.57

Current Price：8.42

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Corbus Pharmaceuticals Holdings Inc (CRBP) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Corbus Pharmaceuticals Holdings Inc (CRBP) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 7.30, the current P/B ratio is approximately -85.34% higher. Relative to its 5-year average P/B ratio of 4.80, the current P/B ratio is about -77.68% higher. Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward Free Cash Flow (FCF) yield of approximately -40.81%. Compared to its 3-year average FCF yield of -63.31%, the current FCF yield is approximately -35.54% lower. Relative to its 5-year average FCF yield of -82.09%, the current FCF yield is about -50.28% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CRBP competitors is 23.53, providing a benchmark for relative valuation. Corbus Pharmaceuticals Holdings Inc Corp (CRBP.O) exhibits a P/S ratio of 131.24, which is 457.71% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CRBP increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CRBP in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CRBP currently overvalued or undervalued?

What is Corbus Pharmaceuticals Holdings Inc (CRBP) fair value?

CRBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Corbus Pharmaceuticals Holdings Inc (CRBP) is between 4.04 to 8.57 according to relative valuation method.

How does CRBP's valuation metrics compare to the industry average?

The average P/S ratio for CRBP's competitors is 23.53, providing a benchmark for relative valuation. Corbus Pharmaceuticals Holdings Inc Corp (CRBP) exhibits a P/S ratio of 131.24, which is 457.71% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Mar 04 2026?

As of Mar 04 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a P/B ratio of 1.07. This indicates that the market values CRBP at 1.07 times its book value.

What is the current FCF Yield for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Mar 04 2026?

As of Mar 04 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a FCF Yield of -40.81%. This means that for every dollar of Corbus Pharmaceuticals Holdings Inc's market capitalization, the company generates -40.81 cents in free cash flow.

What is the current Forward P/E ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Mar 04 2026?

As of Mar 04 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward P/E ratio of -1.31. This means the market is willing to pay $-1.31 for every dollar of Corbus Pharmaceuticals Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Mar 04 2026?

As of Mar 04 2026, Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward P/S ratio of 131.24. This means the market is valuing CRBP at $131.24 for every dollar of expected revenue over the next 12 months.

CRBP Valuation